EFAV
Price
$92.71Alerts
Change
-$0.84 (-0.90%)
Updated
Nov 20 closing price
Net Assets
5.55B
Intraday BUY SELL Signals
GSK
Price
$47.76Alerts
Change
-$0.06 (-0.13%)
Updated
Nov 20 closing price
Capitalization
100.84B
73 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EFAV vs GSK

EFAV vs GSK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EFAV vs. GSK commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EFAV is a Hold and GSK is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EFAV with price predictions
Nov 20, 2026

EFAV's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for EFAV moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 instances where the indicator moved out of the overbought zone. In 35 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a move down at 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EFAV as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for EFAV turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 28 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

EFAV moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EFAV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for EFAV crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Following a +0.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where EFAV advanced for three days, in 270 of 344 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

EFAV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 259 of 345 cases where EFAV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

A.I.Advisor
a Summary for GSK with price predictions
Nov 20, 2026

GSK in downward trend: price dove below 50-day moving average on November 18, 2026

GSK moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 46 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 42 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for GSK turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 22 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.

Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 197 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 136 of 254 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.421). P/E Ratio (20.988) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

FUNDAMENTALS RATINGS
GSK: Fundamental Ratings
GSK
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
PROFIT vs RISK RATING
1..100
39
SMR RATING
1..100
34
PRICE GROWTH RATING
1..100
55
P/E GROWTH RATING
1..100
9
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EFAVGSK
RSI
ODDS (%)
Bearish Trend 3 days ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
57%
Momentum
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
55%
MACD
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
54%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 10 days ago
64%
Declines
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
55%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 4 days ago
50%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement

EFAV and

Correlation & Price change

A.I.dvisor indicates that over the last year, EFAV has been loosely correlated with GSK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if EFAV jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EFAV
1D Price
Change %
EFAV100%
-0.90%
GSK - EFAV
52%
Loosely correlated
-0.13%
SAN - EFAV
52%
Loosely correlated
-2.37%
RIO - EFAV
50%
Loosely correlated
-2.64%
RACE - EFAV
45%
Loosely correlated
-3.20%
RTO - EFAV
44%
Loosely correlated
+0.29%
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-0.13%
NVS - GSK
58%
Loosely correlated
-0.50%
BMY - GSK
58%
Loosely correlated
+0.79%
JNJ - GSK
53%
Loosely correlated
+1.25%
MRK - GSK
53%
Loosely correlated
+0.69%
PFE - GSK
51%
Loosely correlated
-0.51%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
STXT19.040.06
+0.30%
Strive Total Return Bond ETF (STXT)
TBUX49.780.03
+0.06%
T. Rowe Price Ultra Short-Term Bond ETF (TBUX)
FEBZ39.05N/A
N/A
TrueShares Structured Outcome (February) ETF (FEBZ)
HPI12.11-0.16
-1.30%
John Hancock Preferred Income Fund
MPWX9.29-3.10
-25.04%
Tradr 2X Long MPWR Daily ETF (MPWX)